Rate of over-diagnosis of breast cancer 15 years after end of Malmö mammographic screening trial: follow-up study
BMJ 2006; 332 doi: https://doi.org/10.1136/bmj.38764.572569.7C (Published 23 March 2006) Cite this as: BMJ 2006;332:689Data supplement
Appendix 1: [As supplied by authors] Overview of the dates defining analyse periods for the age cohorts. Shaded areas indicate invitation of both invited and control group.
Period 1
(Screening only of invited group)
Period 2
(No screening or screening of both invited and control group)
Birth
cohort
Mean age
at randomisation
Start
End
Start
End
1908
69.9
May 1978
1986¶
1987
2001
1909
68.8
April 1978
1986¶
1987
2001
1910
67.7
March 1978
1986¶
1987
2001
1911
66.7
March 1978
1986¶
1987
2001
1912
65.6
February 1978
1986¶
1987
2001
1913
64.6
January 1978
1986¶
1987
2001
1914
63.5
December 1977
1986¶
1987
2001
1915
62.3
November 1977
1986¶
1987
2001
1916
61.4
November 1977
1986¶
1987
2001
1917
59.7
March 1977
1986¶
1987
2001
1918
58.8
April 1977
Until age 70
From age 71
2001
1919
57.9
June 1977
Until age 70
From age 71
2001
1920
57.2
August 1977
Until age 70
From age 71
2001
1921
55.3
October 1976
Until age 70
From age 71
2001
1922
55.2
September 1977
Until age 70
From age 71
2001
1923
54.3
October 1977
§
December 1991*
2001
1924
52.9
May 1977
§
December 1991*
2001
1925
51.9
June 1977
§
December 1991*
2001
1926
50.6
February 1977
§
Sept 1990/Dec 1991**
2001
1927
49.7
February 1977
§
March 1992*
2001
1928
49.9
May 1978
§
March 1992*
2001
1929
48.3
October 1977
§
May 1992*
2001
1930
48.0
June 1978
§
May 1992*
2001
1931
47.1
August 1978
§
January 1993*
2001
1932
46.2
August 1978
§
February 1993*
2001
¶ End of the trial December 31, 1986.
§ Up to the date for the start of the screening of the control group.
* Average start date for the invitation on the control group.
** Women born first half of the year were invited in the first period, and second half in the second period due to administrative reasons when the screening program started.
Related articles
- This Week In The BMJ Published: 23 March 2006; BMJ 332 doi:10.1136/bmj.332.7543.0-b
- Editorial Published: 23 March 2006; BMJ 332 doi:10.1136/bmj.332.7543.678
- PAPERS Published: 10 March 2004; BMJ doi:10.1136/bmj.38044.666157.63
- Paper Published: 15 April 2004; BMJ 328 doi:10.1136/bmj.38044.666157.63
- Analysis Published: 24 June 2010; BMJ 340 doi:10.1136/bmj.c3106
- Editorial Published: 11 October 2007; BMJ 335 doi:10.1136/bmj.39350.590625.80
- Editorial Published: 09 July 2009; BMJ 339 doi:10.1136/bmj.b1425
- Research Published: 23 November 2011; BMJ 343 doi:10.1136/bmj.d7017
- Research Published: 30 January 2012; BMJ 344 doi:10.1136/bmj.e299
- Observations Published: 02 August 2012; BMJ 345 doi:10.1136/bmj.e5132
- Research Published: 26 February 2013; BMJ 346 doi:10.1136/bmj.f1064
- Research Published: 16 September 2013; BMJ 347 doi:10.1136/bmj.f5334
- Research Published: 11 February 2014; BMJ 348 doi:10.1136/bmj.g366
- Letter Published: 23 March 2006; BMJ 332 doi:10.1136/bmj.332.7543.727
- Letter Published: 23 March 2006; BMJ 332 doi:10.1136/bmj.332.7543.727-a
- Letter Published: 23 March 2006; BMJ 332 doi:10.1136/bmj.332.7543.727-b
- Letter Published: 23 March 2006; BMJ 332 doi:10.1136/bmj.332.7543.728
- Letter Published: 23 March 2006; BMJ 332 doi:10.1136/bmj.332.7543.728-a
- Research Published: 07 January 2015; BMJ 350 doi:10.1136/bmj.g7773
See more
- Breast cancer: Inaction on inequalities has led to unequal progress, say expertsBMJ April 16, 2024, 385 q854; DOI: https://doi.org/10.1136/bmj.q854
- Cancer: Fast tracked drugs often do not improve clinical outcomes, say researchersBMJ April 08, 2024, 385 q818; DOI: https://doi.org/10.1136/bmj.q818
- NHS rolls out fast tracked immunotherapy for advanced endometrial cancerBMJ March 05, 2024, 384 q557; DOI: https://doi.org/10.1136/bmj.q557
- Teledentistry may help in detecting oral cancers in current GP and dentist shortagesBMJ March 01, 2024, 384 q512; DOI: https://doi.org/10.1136/bmj.q512
- UK’s progress on cancer survival has slowed in past decade, figures showBMJ February 02, 2024, 384 q290; DOI: https://doi.org/10.1136/bmj.q290
Cited by...
- Benefits and harms of breast cancer screening revisited: a large, retrospective cross-sectional study quantifying treatment intensity in women with screen-detected versus non-screen-detected cancer in Australia and New Zealand
- Reducing overuse by recognising the unintended harms of good intentions
- Interpretation of breast cancer screening guideline for Chinese women
- Recommendations on screening for breast cancer in women aged 40-74 years who are not at increased risk for breast cancer
- Screening Mammography for Average-Risk Women: The Controversy and NCCN's Position
- Collagen Alignment as a Predictor of Recurrence after Ductal Carcinoma In Situ
- Overdiagnosis of breast cancer in population screening: does it make breast screening worthless?
- Quantifying and monitoring overdiagnosis in cancer screening: a systematic review of methods
- The Early Detection of Pancreatic Cancer: What Will It Take to Diagnose and Treat Curable Pancreatic Neoplasia?
- Twenty five year follow-up for breast cancer incidence and mortality of the Canadian National Breast Screening Study: randomised screening trial
- Were Our Estimates of Overdiagnosis With Mammography Screening * in the United States "Based on Faulty Science"?
- Arguments Against Mammography Screening Continue to be Based on Faulty Science
- Quantification of harms in cancer screening trials: literature review
- Overdiagnosis in screening mammography in Denmark: population based cohort study
- To nudge or not to nudge: cancer screening programmes and the limits of libertarian paternalism
- Cancer, concepts, cohorts and complexity: avoiding oversimplification of overdiagnosis
- How a charity oversells mammography
- Understanding recent trends in incidence of invasive breast cancer in Norway: age-period-cohort analysis based on registry data on mammography screening and hormone treatment use
- Overdiagnosis from non-progressive cancer detected by screening mammography: stochastic simulation study with calibration to population based registry data
- Copy Number Imbalances between Screen- and Symptom-Detected Breast Cancers and Impact on Disease-Free Survival
- Screening for breast cancer--balancing the debate
- Prospective Multicenter Cohort Study to Refine Management Recommendations for Women at Elevated Familial Risk of Breast Cancer: The EVA Trial
- The ethics of basing community prevention in general practice
- Stop treating indolent lesions
- Overdiagnosis and mammography screening
- Participation in mammography screening
- Sporadic and epidemic community legionellosis: two faces of the same illness
- Phenocopies: actual risk or self-fulfilling prophecy?
- Evaluating new screening tests for breast cancer
- Ramifications of screening for breast cancer: 1 in 4 cancers detected by mammography are pseudocancers
- Ramifications of screening for breast cancer: Definition of overdiagnosis is confusing in follow-up of Malmo trial
- Ramifications of screening for breast cancer: More debate and better information still needed
- Over-diagnosis in breast cancer screening
- Ramifications of screening for breast cancer: Overdiagnosis in the Malmo trial was considerably underestimated
- Ramifications of screening for breast cancer: Consent for screening